Spyre Therapeutics
SYRE
64 hedge funds and large institutions have $155M invested in Spyre Therapeutics in 2018 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 22 increasing their positions, 4 reducing their positions, and 6 closing their positions.
450% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 4
433% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 6
85% more capital invested
Capital invested by funds: $84.1M → $155M (+$71.3M)
68% more funds holding
Funds holding: 38 → 64 (+26)
0.66% more ownership
Funds ownership: 2.03% → 2.69% (+0.66%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.85M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$6.31M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$5.01M |
| 4 |
Renaissance Technologies
New York
|
+$4.2M |
| 5 |
Millennium Management
New York
|
+$3.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO)
Austin,
Texas
|
-$1.81M |
| 2 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$649K |
| 3 |
SIM
Spark Investment Management
New York
|
-$188K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$183K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$158K |
SYRE Hedge Fund Activity: Q2 2018 in Review
64 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q2 2018, worth a combined $155M — up 85% from $84.1M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new SYRE positions and 6 closed out — a net gain of 26 holders — while 22 added to existing stakes and 4 trimmed.
The largest buyer was BlackRock, adding an estimated $7.85M. The largest seller was University of Texas/Texas AM Investment Management Co (UTIMCO), cutting an estimated $1.81M.
- 64 institutional investors held Spyre Therapeutics (SYRE) as of Q2 2018, up from 38 in Q1 2018.
- Funds reported $155M of Spyre Therapeutics stock for Q2 2018, up 85% quarter-over-quarter.
- 32 funds opened new Spyre Therapeutics positions in Q2 2018 and 6 closed out, a net change of +26 holders.
- The largest Spyre Therapeutics buyer in Q2 2018 was BlackRock, an estimated $7.85M added.
- The largest Spyre Therapeutics seller in Q2 2018 was University of Texas/Texas AM Investment Management Co (UTIMCO), an estimated $1.81M sold.
Based on aggregated 13F filings for Q2 2018.